Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Travis Koeneke (NPI 1942305677)

Field	Value
Entity Type	Individual
Organization	Travis Koeneke
Address	8301 Positano Dr
City	Manhattan
State	KS
ZIP	66502
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	September 14, 2006

Payer Source	Total Paid
Medicare	$4.4M
Medicaid	$0

Key Findings

This provider’s Medicare book of business is concentrated in high-cost oncology biologics and infusions: J9271 (pembrolizumab) generated $1.7M (40.1% of total Medicare revenue) and J9299 (nivolumab) generated $779.5K (17.9%), with the precomputed top 3 Medicare codes accounting for 66.1% of total Medicare revenue. The code mix — dominated by checkpoint inhibitors and other oncology drugs — indicates the practice operates primarily as a cancer treatment/infusion specialty rather than as a general ambulatory clinic.

Operationally, the claims and administration codes show a full-service infusion practice: high volumes for chemotherapy administration and add‑on infusion codes such as 96413 ($143.9K, 3.3% of Medicare revenue) and multiple add‑on infusion codes (96417, 96411, 96415) indicate frequent IV chemotherapy delivery and multi‑drug sessions. These administration code volumes, together with drug codes like J9264 (paclitaxel protein‑bound particles, $230K, 5.3%), support a workflow centered on infusion nursing and outpatient oncology services.

The provider’s Medicare revenue scale is substantial at $4.4M while there is no Medicaid billing on file; this is effectively a single‑payer (Medicare‑dominated) profile and suggests limited exposure to Medicaid populations or that Medicaid services are billed under a different entity. Absence of Medicaid billing means analyses of in‑state payer mix or Medicaid market share cannot be performed from this record alone.

Competitive standing for core oncology drugs is strong nationally: J9271 ranks #25 of 1841 providers (99th percentile) and is described as notably above typical national volume, while J9299 ranks #60 of 505 providers (88th percentile, typical). Denosumab (J0897) also ranks highly at #343 of 10057 providers (97th percentile) and is described as notably above typical national volume, indicating this clinician is a high‑volume national outlier for several revenue‑driving oncology products.

Several codes are statistical outliers indicating unusually high procedural throughput relative to peers: J1627 (granisetron extended‑release) is rank #1 of 119 providers (100th percentile) and labeled an extreme outlier, 96413 is rank #14 of 7514 (100th percentile, extreme outlier), and 96415 is rank #23 of 4959 (100th percentile, extreme outlier). These extreme outlier labels point to a practice with very high volumes of supportive care and chemotherapy administration compared with national peers.

Supportive care and ancillary medication patterns reinforce an oncology focus: very large claim counts for low‑priced supportive agents (J0185 aprepitant: 61.9K claims, $61.9K revenue, rank #1 of 819 providers, 100th percentile) and agents like J1439 (ferric carboxymaltose) and J1627 indicate routine use of antiemetics, growth‑factor support, and IV iron alongside antineoplastic therapy. The combination of high claim counts and low per‑claim payment for these codes suggests repeated, protocol‑driven supportive interventions accompanying infusion visits.

The provider shows broad utilization across both branded and biosimilar biologics, including Q5115 (rituximab‑abbs, truxima, $168.3K, 3.9%) and Q5108 (pegfilgrastim‑jmdb, $89.1K, 2.0%), signifying a practice that mixes originator agents and biosimilars for hematology/oncology care. National ranks for these biosimilars (Q5115 rank #5 of 79, 95th percentile; Q5108 rank #8 of 125, 94th percentile) indicate above‑typical adoption relative to peers.

Tenure and market footprint: the provider’s NPI was enumerated on 2006-09-14 (~20 years ago), indicating an established practice presence. Combined with $4.4M in lifetime Medicare revenue and multiple high‑percentile ranks across oncology drug and infusion codes, the data portray a long‑standing, high‑volume outpatient oncology operator with concentrated Medicare exposure.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

59 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	40,600	$40	$1.7M
J9299	Injection, nivolumab, 1 mg	32,480	$20	$779.5K
J0897	Injection, denosumab, 1 mg	18,360	$20	$348.8K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	23,000	$10	$230K
J1627	Injection, granisetron, extended-release, 0.1 mg	44,600	$10	$223K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	4,950	$30	$168.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,530	$90	$143.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,170	$90	$107.5K
J9312	Injection, rituximab, 10 mg	1,610	$60	$101.4K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	900	$100	$89.1K

Showing 1–10 of 59

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 59 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Travis Koeneke — 16 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

59 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	20	28,900	$40	$1.1M
J9299	5	10	24,550	$20	$637.2K
J9312	7	10	2,500	$60	$194.7K
Q5115	1	10	2,340	$30	$92.9K
J9264	1	10	6,930	$10	$89.7K
J0897	6	180	2,160	$20	$81.5K
J1627	1	10	15,500	$1	$78.7K
J1439	9	10	41,250	$1	$66.1K
J1449	1	10	2,570	$20	$63.1K
Q5108	2	10	610	$100	$62.7K

Showing 1–10 of 59

Related Providers

Other providers that share a Tax Identification Number (TIN) with Travis Koeneke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0
Shaker Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Travis Koeneke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Big Lakes Developmental Center Inc	KS	Developmentally Disabled Services Day Training Agency	$0	$49.8M
Pawnee Mental Health Service, Inc.	KS	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$25.6M
Pawnee Mental Health Service, Inc.	KS	Community/Behavioral Health Agency	$0	$14M
Pediatric Associates Of Manhattan, P. A.	KS	Pediatric Adolescent Medicine Physician	$0	$4.5M
Sound Physicians Emergency Medicine Of Kansas, LLC	KS	Emergency Medicine Physician	$0	$3.3M
No Stone Unturned Foundation	KS	Physical Therapy Clinic/Center	$0	$2.8M
Manhattan-ogden Usd 383	KS	Local Education Agency (LEA)	$0	$2.7M
Ascension Via Christi Hospital Manhattan, Inc.	KS	General Acute Care Hospital	$0	$1.3M
County Of Riley	KS	Ambulance	$564.6K	$693.9K
Martin Bell	KS	Radiation Oncology Physician	$1M	$0

Travis Koeneke — Billing Profile & Reimbursement Data

Sign up for Travis Koeneke — Billing Profile & Reimbursement Data policy alerts

Travis Koeneke — Billing Profile & Reimbursement Data

Sign up for Travis Koeneke — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References